Actavis Group, the international generic pharmaceuticals company, announced that it has received approval from the US Food & Drug Administration to market Bupropion Hydrochloride extended-release tablets (XL) 300mg. Distribution of the product will commence immediately. Bupropion Hydrochloride extended-release tablets (XL), available in 300mg strength, are the generic equivalent of Wellbutrin XL® for the treatment of major depressive disorder.
Popularity: 1% [?]
Related posts:
- IMPAX Receives Final FDA Approval For Generic Wellbutrin(R) XL 150 Mg
- Aplenzin(TM), The Only Single Tablet Once-Daily Treatment For Depression At All Doses, Now Available In The United States
- Osmotica Pharmaceutical Receives FDA Approval To Market Novel Forms Of Extended Release Venlafaxine HCl
- Biovail Receives Canadian Approval For Wellbutrin(R) XL For The Prevention Of Seasonal Major Depressive Illness
- Barr Receives Tentative Approval For A Generic Version Of ZYPREXA(R) Zydis(R) Tablets, 5mg, 10mg, 15mg And 20mg
Comments
No Responses to “Actavis Receives Approval Of Generic Wellbutrin XL(R) 300mg In The United States”